2nd Model-Informed Drug Development Summit

The 2nd Model-Informed Drug Development Summit is where 60+ senior pharmacometricians, clinical pharmacologists, QSP scientists, translational leaders and regulatory experts come together to work through these questions directly, not in a convention space of a thousand people, but in a room intimate enough that you'll know every name by day three. Unlike the larger association meetings, this is a forum built for depth over volume: expert-led case studies, candid conversations around strategy, and connections that actually go somewhere after the event ends.

Across a workshop day and two conference days, expect practical, modality-agnostic conversations spanning AI-assisted modelling, the pharmacometrics-biostatistics interface, internal and regulatory stakeholder buy-in.


URLs:
Website: https://go.evvnt.com/3772316-0?pid=2874
Brochure: https://go.evvnt.com/3772316-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Prices:
Conference + Workshop Day - Drug Developer Pricing: USD 4397.00,
Conference Only - Drug Developer Pricing: USD 3099.00,
Conference + Workshop Day - Academic Pricing: USD 3797.00,
Conference Only - Academic Pricing: USD 2699.00,
Conference + Workshop Day - Service Provider Pricing: USD 5297.00,
Conference Only - Service Provider Pricing: USD 3799.00

Speakers: Azar Shahraz, Director of Clinical Pharmacology, Abbvie, Jiayin Huang, Senior Director, Clinical Pharmacology Modeling and Simulation, Amgen, Souvik Bhattacharya, Associate Director of Pharmacometrics, Astellas Pharma, Hongmei Xu, VP, Quantitative Pharmacology, Bicycle Therapeutics, Caroline Sychterz, Director, Bristol Myers Squibb, Arunava Chakravartty, Associate Vice President of Biostatistics, Eli Lilly, Jatinder Mukker, Senior Director and Head of Quantitative Pharmacology Portfolio, EMD Serono, Yuan Chen, Senior Fellow, Genentech, Fulya Akpinar Singh, Director, Genmab, Angelica Davenport, Senior Scientist, Clinical Pharmacology and Quantitative Science, Genmab, Sandhya Girish, Vice President of Clinical Pharmacology Sciences, Gilead Sciences, Julia Korell, Executive Director and Head of Pharmacometrics, GlaxoSmithKline, Yueming Wang, Senior Principal Scientist and Leader, Clinical Pharmacology, Johnson and Johnson Innovative Medicine, Ying Fei Li, Director of Pharmacometrics, Novartis, Raj Macha, Global Head of Pharmacometrics/Quantitative Pharmacology, Sanofi, Bart Borek, Associate Director, Clinical and Quantitative Pharmacology, Vertex Pharmaceuticals, Lindsay Kehoe, Senior Project Manager, Clinical Trials Transformation Initiative (CTTI), Hao Zhu, Division Director, FDA, Sarem Sarem, Co-Chair Pharmacometrics WG, Pharmaceutical Drugs Directorate, Health Canada